Detection of MYD88 L265P in peripheral blood of patients with WaldenstrÃ¶m's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

[waldenstrÃ¶m macroglobulinemia]

MYD 88 L 265 P is highly prevalent in Waldenstrom 's Macroglobulinemia (WM ) and IgM monoclonal gammopathy of unknown significance (MGUS ). We investigated whether MYD 88 L 265 P could be identified by peripheral blood (PB ) allele-specific PCR . MYD 88 L 265 P was detected in untreated WM (114 /118 ; 96 .6 %); previously treated WM (63 /102 ; 61 .8 %); and IgM MGUS (5 /12 ; 41 .7 %) but in none of 3 hyper-IgM or 40 healthy individuals . Median PB MYD 88 L 265 P Î”Ct was 3 .77 , 7 .24 , 10 .89 , 12 .33 and 14 .07 for untreated WM , previously treated WM , IgM MGUS , hyper-IgM and healthy individuals , respectively (P <0 .0001 ). For the 232 IgM MGUS and WM patients , PB MYD 88 L 265 P Î”Ct moderately correlated to bone marrow (BM ) disease (r =-0 .3553 ; P <0 .0001 ), serum IgM (r =-0 .3262 ; P <0 .0001 ) and hemoglobin (r =0 .3005 ; P <0 .0001 ) levels . PB MYD 88 L 265 P Î”Ct and serum IgM correlated similarly with BM disease burden . For positive patients , PB MYD 88 L 265 P Î”Ct was <6 .5 in 100 /114 (88 %) untreated WM , and >6 .5 in 4 /5 (80 %) IgM MGUS patients (P =0 .0034 ). Attainment of a negative PB MYD 88 L 265 P mutation status was associated with lower BM disease (P =0 .001 ), serum IgM (P =0 .019 ) and higher hemoglobin (P =0 .004 ) levels in treated patients . These studies show the feasibility for detecting MYD 88 L 265 P by PB examination , and the potential for PB MYD 88 L 265 P Î”Ct use in the diagnosis and management of WM patients .

Diseases
Validation

Diseases presenting "lower bm disease" symptom

waldenstrÃ¶m macroglobulinemia

You can validate or delete this automatically detected symptom